From guidelines to action
This project aims to help the heart failure community advocate for change to close the gap between clinical guidelines and the reality of care for people living with heart failure.
Find out more
Spotlight series
The Spotlight series features evidence-based reports on topics at the forefront of debates about the future of heart failure care.
Find out more
Action Statement on Heart Failure
A call to action outlining clear policy recommendations for European institutions to address the growing burden of heart failure.
Find out more
heart graphic

Helping advance meaningful policy change on heart failure

The Heart Failure Policy Network is an independent, multidisciplinary platform of healthcare professionals, advocacy groups and policymakers from across Europe.

We aim to raise awareness of the unmet needs surrounding heart failure and its care, and to help drive meaningful changes in policy and practice.

Find out more
Latest
New guideline recommendations on iron deficiency could improve quality of life for people with heart failure
29 June 2022

The updated ESC guidelines recommend that all people with heart failure be screened for iron deficiency, and provided new treatment recommendations.

Read article
Latest
Guideline changes offer opportunity to demand better care for people with heart failure
15 June 2022

HFPN supports the heart failure community in its efforts to drive actionable change and make a real impact on the care and treatment of people with heart failure.

Read article
Latest
Are we failing women with heart failure?
7 June 2022

It has been argued that women are systematically discriminated against in healthcare, so what does this mean for women with heart failure?

Read article
heart failure graphic
What is heart failure?

Affecting at least 15 million adults in Europe, heart failure is a common but complex clinical syndrome that occurs when the heart is unable to pump enough blood to meet body’s needs.

Its prevalence is expected to rise due to population ageing and improved survival rates for other long-term conditions, including cardiovascular diseases.

Find out more
The Heart Failure Policy Network is made possible with financial support from AstraZeneca, Vifor Pharma, Bayer AG and Boehringer Ingelheim. The content produced by the Network is non-promotional and not biased to any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members.